1.Scagliotti GV，Parikh P，von Pawel J，et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol，2008，26（21）：3543-3551.

2.Sandler A，Gray R，Perry MC，et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med，2006，355（24）：2542-2550.

3.Kris MG，Johnson BE，Berry LD，et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA，2014，311（19）：1998-2006.

4.Sholl LM，Aisner DL，Varella-Garcia M，et al.Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma：The Lung Cancer Mutation Consortium Experience.J Thorac Oncol，2015，10（5）：768-777.

5.Barlesi F，Mazieres J，Merlio JP，et al. Biomarkers France contributors.Routine molecular profiling of patients with advanced non-small-cell lung cancer：results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup（IFCT）. Lancet，2016，pii：S0140-6736（16）00004-0.

6.Seo JS，Ju YS，Lee WC，et al.The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res，2012，22（11）：2109-2119.

7.An SJ，Chen ZH，Su J，et al.Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One，2012，7（6）：e40109.

8.Ren S，Kuang P，Zheng L，et al.Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys，2012，64（2）：155-160.

9.Seo JS，Ju YS，Lee WC，et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res，2012，22（11）：2109-2119.

10.Paez JG，Jänne PA，Lee JC，et al. EGFR mutations in lung cancer：correlation with clinical response to gefitinib therapy. Science，2004，304（5676）：1497-1500.

11.Lynch TJ，Bell DW，Sordella R，et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med，2004，350（21）：219-239.

12.Gao G，Ren S，Li A，et al.Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as firstline treatment of advanced non small-cell lung cancer with mutated EGFR：a meta-analysis from six phase Ⅲrandomized controlled trials. Int J Cancer，2012，131（5）：E822-E829.

13.Yu HA，Arcila ME，Rekhtman N，et al. Analysis of tumor specimens at the time of acquired resistance to EGFRTKI therapy in 155 patients with EGFR-mutant lung cancers.Clin Cancer Res，2013，19（8）：2240-2247.

14.Jänne PA，Yang JC-H，Kim D-W，et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med，2015，372（18）：1689-1699.

15.Sequist LV，Soria JC，Goldman JW，et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med，2015，372（18）：1700-1709.

16.Soda M，Choi YL，Enomoto M，et al：Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature，2007，448（7153）：561-566.

17.Tsao MS，Hirsh FR，Yatabe Y（eds）：IASLC Atlas of ALK Testing in Lung Cancer. Aurora，CO International Association for the Study of Lung Cancer，2013.

18.Shi YK，Liu TH，Sun Y，et al. Guideline for Diagnosis and treatment of Non-small cell lung cancer patients with Epidermal Growth Factor Receptor mutation or Anaplastic Lymphoma Kinase rearrangement（2013）：Oncology branch of Chinese Medical Doctor Association Chemotherapy Committee of Chinese Anti-cancer Association. Chin J Oncol，2013，35（6）：478-479.

19.Zhang X，Lu S，Wu YL，et al. The diagnostic of anaplastic lymphoma kinase（ALK） positive non-small cell lung cancer：Chinese expert consensus（2013）.Chin J Pathol，2013，42：402-406.

20.Solomon BJ，Mok T，Kim DW，et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med，2014，371（23）：2167-2177.

21.Iragavarapu C，Mustafa M，Akinleye A，et al. Novel ALK inhibitors in clinical use and development. J Hematol Oncol，2015，8（1）：17.

22.Maus MK，Grimminger PP，Mack PC，et al. KRAS mutations in non-small-cell lung cancer and colorectal cancer：implications for EGFR-targeted therapies. Lung Cancer，2014，83（2）：163-167.

23.Janne PA，Shaw AT，Pereira JR，et al. Phase II double-blind，randomized study of selumetinib（SEL） plus docetaxel（DOC） versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer（NSCLC）. J Clin Oncol，2012（suppl；abstr 7503）.

24.Shaw AT，Ou SH，Bang YJ，et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med，2014，371（21）：1963-1971.

25.Peters S1，Michielin O，Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol，2013，31（20）：e341-e344.

26.David Planchard，Julien Mazieres，Gregory J. Riely，et al. Interim results of phase Ⅱ study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer（NSCLC） patients. J Clin Oncol，2013（suppl；abstr 8009）.

27.Pritchard KI1，Shepherd LE，O’Malley FP，et al. National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med，2006，354（20）：2103-2111.

28.Saura C，Garcia-Saenz JA，Xu B，et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol，2014，32（32）：3626-3633.

29.De Grève J，Teugels E，Geers C，et al. Clinical activity of afatinib（BIBW 2992） in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer，2012，76（1）：123-127.

30.Mazières J1，Peters S，Lepage B，et al. Lung cancer that harbors an HER2 mutation：epidemiologic characteristics and therapeutic perspectives.J Clin Oncol，2013，31（16）：1997-2003.

31.Drilon A，Wang L，Hasanovic A，et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov，2013，3（6）：630-635.

32.Vaishnavi A1，Capelletti M，Le AT，et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med，2013，19（11）：1469-1472.

33.Akinleye A，Furqan M，Mukhi N，et al. MEK and the inhibitors：from bench to bedside. J Hematol Oncol，2013，6：27.

34.Recio JA，Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK，ATF-2 and cyclin D1.Oncogene，2002，21（7）：1000-1008.

35.Paumelle R，Tulasne D，Kherrouche Z，et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEKERK signaling pathway. Oncogene，2002，21（15）：2309-2319.

36.Camidge DR，Ou SI，Shapiro G，et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer（NSCLC）. J Clin Oncol，2014，32：5s（suppl），abstr 8001.

37.Pan Y，Wang R，Ye T，et al. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest，2014，145（3）：473-479.

38.Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature，2012，489（7417）：519-525.

39.Kim Y，Hammerman PS，Kim J，et al .Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol，2014，32（2）：121-128.

40.Perez-Moreno P，Brambilla E，Thomas R，et al. Squamous cell carcinoma of the lung：molecular subtypes and therapeutic opportunities. Clin Cancer Res，2012，18（9）：2443-2451.

41.Turner N，Grose R. Fibroblast growth factor signalling：from development to cancer. Nat Rev Cancer，2010，10（2）：116-129.

42.Weiss J SML，Seidel Dea. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med，2010，2（62）：62-93.

43.Göke F，Franzen A，Hinz TK，et al. FGFR1 expression levels predict BGJ398-sensitivity of FGFR1-dependent head and neck squamous cell cancers.Clin Cancer Res，2015，21（19）：4356-4364.

44.Ikeda K，Wang LH，Torres R，et al. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem，2002，277（21）：19206-19212.

45.Perez-Moreno P，Brambilla E，Thomas R，et al. Squamous cell carcinoma of the lung：molecular subtypes and therapeutic opportunities. Clin Cancer Res，2012，18（9）：2443-2451.

46.Hammerman PS，Sos ML，Ramos AH，et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov，2011，1（1）：78-89.

47.Pitini V，Arrigo C，Di Mirto C，et al. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer，2013，82（1）：171-172.

48.Yamamoto H，Shigematsu H，Nomura M，et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res，2008，68（17）：6913-6921.

49.Thomas RK，Baker AC，Debiasi RM，et al. High throughput oncogene mutation profiling in human cancer. Nat Genet，2007，39（3）：347-351.

50.Govindan R，Ding L，Griffıth M，et al. Genomic landscape of non-small cell lung cancer in smokers and neversmokers. Cell，2012，150（6）：1121-1134.

51.Soria JC，Lee HY，Lee JI，et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res，2002，8（5）：1178-1184.

52.Spoerke JM，O’Brien C，Huw L，et al. Phosphoinositide 3-kinase（PI3K） pathway alterations are associated with histologic subtypes andare predictive of sensitivity to PI3K inhibitors in lung cancer preclinicalmodels. Clin Cancer Res，2012，18（24）：6771-6783.

53.Engelman JA，Chen L，Tan X，et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med，2008，14（12）：1351-1356.

54.Rudin CM，Durinck S，Stawiski EW，et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet，2012，44（10）：1111-1116.

55.Peifer M，Fernández-Cuesta L，Sos ML，et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet，2012，44（10）：1104-1110.

56.Pietanza MC. Prospective molecular evaluation of small cell lung cancer（SCLC） utilizing the comprehensive Mutation Analysis Program（MAP） at Memorial Sloan Kettering Cancer Center（MSKCC）. 2014，ESMO 14630.